

IMAGING SCIENCE, END TO END. AND THE DISCOVERY BIOLOGY AROUND IT.

I am Lucas Thal, PhD, an independent imaging scientist for biotech teams, CROs, tool companies and investors. I find where an image-based assay breaks, in the design, the acquisition, the analysis or the statistics, and fix it before it drives a decision.

Images that hold up. Assay design, acquisition and analysis for high-content and advanced microscopy, from fluorophore choice to the statistics. You get a pipeline you can rerun and a phenotype you can defend.

Human models you can trust. iPSC neuron, astrocyte and microglia mono- and tri-cultures with explicit QC gates that separate disease biology from differentiation noise, and readouts chosen for the question.

A cascade, not a pile of assays. Biochemical to functional to translational, with go/no-go criteria at every tier, for small molecules, antibodies, siRNA and ASOs.

Strategy that gets a program to the next gate. Go/no-go criteria, build versus outsource, CRO selection and oversight, and scientific diligence, written for the people who have to make the call.

WHERE TO START

Assay Cascade Design Sprint — From \$12,000. Cascade Design Dossier, 15–30 pages.

Imaging and Functional Readout Audit — From \$8,000. Readout Audit Report, 10–20 pages, with an optional rerunnable notebook.

Scientific Diligence Memo — From \$10,000. Diligence Memo, 8–15 pages, with a red-flag table.

Neurocrine Biosciences, Senior Scientist 2021–2025 · PhenoVista Biosciences · Vanderbilt PhD, Chemical Biology · Lawrence Berkeley National Lab · Ten publications, 300+ citations · San Diego

lucas@thalamusbio.com · <https://thalamusbio.com>